<DOC>
<DOCNO>
EP-0002930
</DOCNO>
<TEXT>
<DATE>
19790711
</DATE>
<IPC-CLASSIFICATIONS>
C07C-209/00 C07D-333/20 C07C-211/00 C07C-209/60 C07C-261/04 C07D-409/12 C07C-129/08 C07C-303/00 A61K-31/495 C07D-209/48 A61K-31/38 C07C-323/48 C07D-333/00 C07D-409/00 C07C-323/29 C07D-213/00 A61K-31/34 A61K-31/345 C07D-307/28 C07C-261/00 C07C-323/44 C07C-217/48 C07D-405/00 A61P-1/00 A61K-31/13 C07C-311/00 A61P-1/04 C07D-295/096 C07C-217/00 C07C-211/29 C07C-275/32 C07C-335/00 C07C-67/00 C07C-275/00 C07C-301/00 C07D-405/12 C07D-213/32 A61K-31/17 C07D-307/52 A61K-31/40 C07D-295/12 C07C-325/00 C07C-127/00 C07D-307/00 C07C-323/47 C07C-303/36 C07C-313/00 A61K-31/341 C07D-295/00 C07D-307/38 C07C-335/08 C07C-311/64 <main>C07D-307/52</main> A61K-31/505 C07C-303/40 C07D-209/00 C07C-323/00 A61K-31/381 
</IPC-CLASSIFICATIONS>
<TITLE>
amine derivatives, their preparation and pharmaceutical compositions containing them.
</TITLE>
<APPLICANT>
glaxo group ltdgb<sep>glaxo group limited<sep>glaxo group limitedclarges house 6-12 clarges streetlondon w1y 8dhgb<sep>glaxo group limited<sep>
</APPLICANT>
<INVENTOR>
bradshaw john<sep>clitherow john watson<sep>martin-smith michael<sep>price barry john<sep>bradshaw, john<sep>clitherow, john watson<sep>martin-smith, michael<sep>price, barry john<sep>bradshaw, john22 whitely closedane end, nr. ware hertfordshiregb<sep>clitherow, john watson54 gilderssawbridgeworth hertfordshiregb<sep>martin-smith, michael'leycroft' the street haultwickdane end, nr. ware hertfordshiregb<sep>price, barry john155 ware roadhertford hertfordshiregb<sep>bradshaw, john<sep>clitherow, john watson<sep>martin-smith, michael<sep>price, barry john<sep>bradshaw, john22 whitely closedane end, nr. ware hertfordshiregb<sep>clitherow, john watson54 gilderssawbridgeworth hertfordshiregb<sep>martin-smith, michael'leycroft' the street haultwickdane end, nr. ware hertfordshiregb<sep>price, barry john155 ware roadhertford hertfordshiregb<sep>
</INVENTOR>
<ABSTRACT>
the invention relates to compounds of the general  formula (i)    and physiologically acceptable salts, n-oxides, hydrates  and bioprecursors thereof, in which y represents =0, =s,  =chno₂ or =nr₃ where r₃ represents hydrogen, nitro,  cyano, lower alkyl, aryl, lower alkylsulphonyl or arylsulphonyl;  r₁ and r₂, which may be the same or different,  each represent hydrogen lower alkyl, cycloalkyl, lower  alkenyl, aralkyl, hydroxy, lower trifluoroalkyl, lower alkyl  substituted by hydroxy, lower alkoxy, amine, lower alkylamino  or dialkylamino, or r₁ and r₂ together with the  nitrogen atom to which they are attached form a 5 to 7  membered heterocyclic ring which may contain other  heteroatoms or the group    where r₄ represents hydrogen or lower alkyl; q represents  a furan or thiophen ring in which incorporation into  the rest of the molecule is through bonds at the 2- and  5-positions, or a benzene ring in which incorporation into  the rest of the molecule is through bonds at the 1- and  3- or 1- and 4-positions;   x represents -ch₂-, -o- or -s-;   n represents zero, 1 or 2;   m represents 2, 3 or 4;   alk represents a straight chain alkylene group of 1 to 3  carbon atoms;  (except that n is not zero when x is oxygen and q is  a furan or thiophen ring system)   q represents 2, 3, or 4 or can additionally represent zero  or 1 when e is a -ch₂-group;   p represents zero, 1 or 2;   e represents -ch₂-, -o- or -s-; and   z represents a monocyclic 5 or 6 membered carbocyclic  or heterocyclic aromatic ring which may be optionally  substituted by one or more groups or z  represents the group  
</ABSTRACT>
</TEXT>
</DOC>
